Association between patient age and gabapentin serum concentration-to-dose ratio -: A preliminary multivariate analysis

被引:30
作者
Armijo, JA [1 ]
Pena, MA [1 ]
Adín, J [1 ]
Vega-Gil, N [1 ]
机构
[1] Univ Cantabria, Serv Farmacol Clin, Hosp Univ Marques Valdecilla, Sch Med, E-39008 Santander, Spain
关键词
gabapentin; concentration-to-dose ratio; therapeutic drug monitoring; age influence; dosage influence; antiepileptic drugs; epilepsy;
D O I
10.1097/00007691-200412000-00008
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Objectives: To evaluate the association between patient age and gabapentin (GBP) concentration-to-dose ratio by a multivariate analysis. Methods: The association between patient age and the trough steady-state serum concentration of gabapentin (GBP) normalized to 1 mg/kg body weight or concentration-to-dose ratio (CDR) was retrospectively assessed by analysis of covariance. Potential confounding factors considered were GBP dosage, the number of GBP doses per day, and the presence of concomitant antiepileptic drugs (AEDs). Concentrations that had been measured in predose "trough" samples collected from 66 patients, aged 5-84 years, with partial seizures or neuropathic pain chronically receiving GBP BID (n = 21) or TID (n = 45), alone (n = 15) or in combination with other AEDs (n = 51) were used in this retrospective analysis. Results: Average GBP CDR was 0.23 +/- 0.18 (mean SD). The GBP CDR increased with age (r(2) = 0.46, P < 0.001), and the correlation was improved when only samples from patients taking GBP BID were separately considered (r(2) = 0.68, P < 0.001). The ratio was lower in the 10 children younger than 11 years of age (0.07 +/- 0.05) than in 8 adolescents aged 12 to 18 years (0.14 +/- 0.04), lower than in 35 adults aged 19 to 65 years (0.22 +/- 0.13), and lower than in 13 patients older than 65 years of age (0.45 +/- 0.20) by 1-way analysis of variance (F = 19.4, P < 0.001). Analysis of covariance showed a significant influence on GBP CDR of patient age (P < 0.001) and the number of GBP daily doses (P < 0.01), but GBP daily dosage or concomitant AEDs had no significant influence on the ratio. Conclusions: In this retrospective study of a small, select group of patients, (1) the GBP CDR increased significantly with age when potential confounding factors such as GBP dosage, number of GBP doses per day, and concomitant AEDs were considered by analysis of covariance, and (2) patients older than 65 years, even without any known renal disease, may have double GBP CDR than younger adults and, therefore, may need half of the GBP dose per body weight to achieve a similar concentration.
引用
收藏
页码:633 / 637
页数:5
相关论文
共 18 条
[1]   Gabapentin does not affect antipyrine clearance [J].
Allen, E ;
Tsanaclis, LM ;
Wroe, SJ ;
Reece, PA ;
Sedman, AJ .
JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 39 (09) :934-935
[2]   Gabapentin monotherapy .1. An 8-day, double-blind, dose-controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures [J].
Bergey, GK ;
Morris, HH ;
Rosenfeld, W ;
Blume, WT ;
Penovich, PE ;
Morrell, MJ ;
Leiderman, DB ;
Crockatt, JG ;
LaMoreaux, L ;
Garofalo, E ;
Pierce, M .
NEUROLOGY, 1997, 49 (03) :739-745
[3]   Gabapentin monotherapy .2. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures [J].
Beydoun, A ;
Fischer, J ;
Labar, DR ;
Harden, C ;
Cantrell, D ;
Uthman, BM ;
Sackellares, JC ;
AbouKhalil, B ;
Ramsay, RE ;
Hayes, A ;
Greiner, M ;
Garofalo, E ;
Pierce, M .
NEUROLOGY, 1997, 49 (03) :746-752
[4]   PHARMACOKINETICS OF GABAPENTIN IN SUBJECTS WITH VARIOUS DEGREES OF RENAL-FUNCTION [J].
BLUM, RA ;
COMSTOCK, TJ ;
SICA, DA ;
SCHULTZ, RW ;
KELLER, E ;
REETZE, P ;
BOCKBRADER, H ;
TUERCK, D ;
BUSCH, JA ;
REECE, PA ;
SEDMAN, AJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (02) :154-159
[5]   Effects of age and gender on single-dose pharmacokinetics of gabapentin [J].
Boyd, RA ;
Türck, D ;
Abel, RB ;
Sedman, TJ ;
Bockbrader, HN .
EPILEPSIA, 1999, 40 (04) :474-479
[6]   LAMOTRIGINE, A NEW ANTICONVULSANT - PHARMACOKINETICS IN NORMAL HUMANS [J].
COHEN, AF ;
LAND, GS ;
BREIMER, DD ;
YUEN, WC ;
WINTON, C ;
PECK, AW .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 42 (05) :535-541
[7]   Gabapentin: A unique anti-epileptic agent [J].
Dougherty, JA ;
Rhoney, DH .
NEUROLOGICAL RESEARCH, 2001, 23 (08) :821-829
[8]   ANALYSIS OF TAURINE IN BLOOD-PLASMA OF EPILEPTIC PATIENTS USING AN IMPROVED ISOCRATIC HPLC METHOD FOR AMINO-ACIDS [J].
ESLAMI, M ;
STUART, JD ;
DEAN, RW .
JOURNAL OF LIQUID CHROMATOGRAPHY, 1987, 10 (05) :977-995
[9]   Plasma gabapentin concentrations in children with epilepsy: Influence of age, relationship with dosage, and preliminary observations on correlation with clinical response [J].
Gatti, G ;
Ferrari, AR ;
Guerrini, R ;
Bonanni, P ;
Bonomi, I ;
Perucca, E .
THERAPEUTIC DRUG MONITORING, 2003, 25 (01) :54-60
[10]   GABAPENTIN - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND CLINICAL POTENTIAL IN EPILEPSY [J].
GOA, KL ;
SORKIN, EM .
DRUGS, 1993, 46 (03) :409-427